JS001 is named as an intervention in 25 current clinical trials in our China, USA, Canada and Australia registers. 16 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is RemeGen Co., Ltd (7). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 3 |
| Recurrent Nasopharyngeal Carcinoma | 3 |
| Urothelial Carcinoma | 2 |
| Gastric Cancer | 2 |
| Nasopharyngeal Cancer Recurrent | 1 |
| Stomach Neoplasms | 1 |
| Advanced Malignant Solid Tumors | 1 |
| Esophageal Squamous Cell Carcinoma Stage II | 1 |
| Esophageal Squamous Cell Carcinoma Stage III | 1 |
| HER2-expressing | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Bladder Cancer | 1 |
| Pancreatic Cancer | 1 |
| Biliary Tract Cancer (BTC) | 1 |
| Advanced Solid Tumor | 1 |
| Muscle-Invasive Bladder Carcinoma | 1 |
| Programmed Cell Death Protein 1 Inhibitor | 1 |
| Radiotherapy | 1 |
| Esophageal Cancer | 1 |
| Chemoradiotherapy | 1 |
| Hepatocellular Carcinoma | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Metastasis | 1 |
| Chemotherapy | 1 |
| Immunotherapy | 1 |
| HR-positive,HER2-negative Breast Cancer | 1 |
| Urothelial Carcinoma Bladder | 1 |
| Urothelial Carcinoma Recurrent | 1 |
| Urothelial Carcinoma of the Renal Pelvis and Ureter | 1 |
| Nasopharyngeal Cancer | 1 |
| Advanced Esophageal Squamous Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| RemeGen Co., Ltd | 7 |
| Sun Yat-sen University | 5 |
| Shanghai Junshi Bioscience Co., Ltd | 3 |
| Fudan University | 3 |
| Coherus Oncology, Inc | 1 |
| Wan He | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Cancer Hospital of Guangxi Medical University | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Mabwell (Shanghai) Bioscience Co., Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 24 | 15 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
25 current trials in our China, USA, Canada and Australia registers name JS001 as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 16 of the 25 trials are recruiting: 15 with sites in China, 1 with sites in USA and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
RemeGen Co., Ltd (7), Sun Yat-sen University (5), Shanghai Junshi Bioscience Co., Ltd (3) and Fudan University (3), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JS001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JS001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JS001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.